Yousif Capital Management LLC Has $13.40 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Yousif Capital Management LLC lessened its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 7.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 261,106 shares of the biopharmaceutical company’s stock after selling 19,824 shares during the quarter. Yousif Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $13,397,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. OFI Invest Asset Management bought a new stake in Bristol-Myers Squibb in the third quarter worth approximately $25,000. Milestone Investment Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at $27,000. Blue Bell Private Wealth Management LLC lifted its position in shares of Bristol-Myers Squibb by 61.5% during the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 200 shares during the period. Legacy Financial Group LLC bought a new position in Bristol-Myers Squibb during the third quarter worth $39,000. Finally, VisionPoint Advisory Group LLC grew its holdings in Bristol-Myers Squibb by 300.5% in the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 553 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of Bristol-Myers Squibb stock traded down $0.14 during trading hours on Wednesday, hitting $48.85. 12,560,325 shares of the company’s stock traded hands, compared to its average volume of 15,477,577. The stock has a market capitalization of $99.01 billion, a price-to-earnings ratio of 12.60, a PEG ratio of 1.48 and a beta of 0.39. Bristol-Myers Squibb has a 12-month low of $47.58 and a 12-month high of $70.93. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. The company has a fifty day simple moving average of $51.22 and a 200-day simple moving average of $51.32.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.15. The business had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The firm’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter last year, the company posted $1.82 earnings per share. Equities research analysts anticipate that Bristol-Myers Squibb will post 6.63 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 4.91%. Bristol-Myers Squibb’s payout ratio is 62.18%.

Analyst Ratings Changes

Several brokerages have recently weighed in on BMY. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price target for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $61.18.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.